Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study
| Autor: | E Fokkema, H. J. Hoekstra, P. R. Timmer, A. H. W. van der Leest, J. Hermans, J Nabers, J. W. G. van Putten, G.D. Nossent, Renée Otter, Nanno Mulder, Willem M. Smit, E.G.E. de Vries, Harry J.M. Groen |
|---|---|
| Přispěvatelé: | Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS) |
| Rok vydání: | 2004 |
| Předmět: |
Male
Radiation-Sensitizing Agents medicine.medical_specialty Radiosensitizer Lung Neoplasms medicine.medical_treatment stage III NSCLC Gastroenterology Disease-Free Survival chemistry.chemical_compound Carcinoma Non-Small-Cell Lung Internal medicine Pulmonary fibrosis ONCOLOGY-GROUP Humans Medicine CYTOTOXICITY HYPERFRACTIONATED RADIATION-THERAPY Infusions Intravenous Lung cancer radiotherapy Etoposide Cisplatin business.industry Respiratory disease DNA Hematology CONCURRENT CHEMOTHERAPY Middle Aged medicine.disease Combined Modality Therapy Carboplatin Surgery Survival Rate Radiation therapy PLATINUM DRUGS Oncology chemistry ETOPOSIDE carboplatin Quality of Life TRIAL Female radiosensitization business Follow-Up Studies medicine.drug |
| Zdroj: | Annals of Oncology, 15(3), 427-432. Oxford University Press |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdh100 |
| Popis: | To determine the radiosensitizing effect of prolonged exposure of carboplatin in patients with locally unresectable non-small-cell lung cancer (NSCLC).Patients with histologically proven NSCLC, performance score2, weight loss10%, and normal organ functions were randomized between carboplatin 840 mg/m2 administered continuously during 6 weeks of radiotherapy or thoracic radiotherapy alone (both 60 Gy). Toxicity was evaluated with National Cancer Institute Common Toxicity Criteria (NCI CTC) and the Radiation Therapy Oncology Group (RTOG) criteria. Quality of life was measured with European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30/LC13 questionnaires.One-hundred and sixty patients were included. Pathologically confirmed persistent tumor was present in 53% of patients in the combination arm versus 58% in the radiotherapy alone arm (P=0.5). Median survival in the combination arm was 11.8 [95% confidence interval (CI) 9.3-14.2] months and in the radiotherapy alone arm 11.7 (95% CI 8.1-15.5) months; progression-free survival was not different between arms [6.8 and 7.5 months, respectively (P=0.28)]. Acute toxicity was mild, late toxicity was radiation-induced cardiomyopathy (three patients) and pulmonary fibrosis (five patients). Quality of life was not different between arms, but in all measured patients cough and dyspnea improved, pain became less, and slight paresthesia developed 3 months after treatment.Addition of continuously administered carboplatin as radiosensitizer for locally unresectable NSCLC does not improve local tumor control or overall survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|